Clinicians are using Roche's Cobas Omni Utility Channel to run lab-developed PCR tests alongside in vitro diagnostic kits, freeing valuable resources for labs.
The test has been validated for use with the same full set of female urogenital specimens that are used with Cobas NT/NG testing, as well as for use with male urine.
The financing will go toward efforts by the German firm to bring its point-of-care screening system for drug-resistant bacteria to hospitals.
The researchers found that Cepheid's Xpert HCV viral load assay used at the point of care performed at levels comparable to a laboratory test.
The firm said that the RealTime CMV test is the only commercially available cytomegalovirus that can amplify two select regions of the CMV genome.
The firm does not meet a listing requirement calling for at least $2.5 million in stockholders equity and has 45 days to submit a plan to regain compliance.
While molecular testing is now routine in cancer and women's health, for other disease areas, the technology may be overkill, Sundin said.
The funding will support manufacturing of the firm's Idylla PCR-based diagnostics platform and worker training at its Mechelen, Belgium facility.
With this clearance, the respiratory pathogen panel is ready to enter the market to aid in accurate patient diagnosis for respiratory illness.
Transgenomic has completed its divestment of its Genetic Assays and Platforms unit to Adstec
A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.
A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.
Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.
In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.